WO2001094629A3 - Cancer gene determination and therapeutic screening using signature gene sets - Google Patents

Cancer gene determination and therapeutic screening using signature gene sets Download PDF

Info

Publication number
WO2001094629A3
WO2001094629A3 PCT/US2001/010838 US0110838W WO0194629A3 WO 2001094629 A3 WO2001094629 A3 WO 2001094629A3 US 0110838 W US0110838 W US 0110838W WO 0194629 A3 WO0194629 A3 WO 0194629A3
Authority
WO
WIPO (PCT)
Prior art keywords
genes
sets
gene
expression
methods
Prior art date
Application number
PCT/US2001/010838
Other languages
French (fr)
Other versions
WO2001094629A2 (en
WO2001094629A8 (en
Inventor
Paul E Young
Meena Augustus
Kenneth C Carter
Reinhard Ebner
Greg Endress
Steve Horrigan
Daniel R Soppet
Zoe Weaver
Original Assignee
Avalon Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avalon Pharmaceuticals filed Critical Avalon Pharmaceuticals
Priority to EP01938990A priority Critical patent/EP1358349A2/en
Priority to AU2001264559A priority patent/AU2001264559A1/en
Priority to CA002411601A priority patent/CA2411601A1/en
Priority to JP2002502169A priority patent/JP2004509612A/en
Publication of WO2001094629A2 publication Critical patent/WO2001094629A2/en
Publication of WO2001094629A8 publication Critical patent/WO2001094629A8/en
Publication of WO2001094629A3 publication Critical patent/WO2001094629A3/en
Priority to US10/843,641 priority patent/US20050064454A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Processes for assaying potential antitumor agents based on their modulation of the expression of specified genes, or sets, of suspected cancer cell genes are disclosed, along with methods for diagnosing cancerous, or potentially cancerous, conditions as a result of the expression, or patterns of expression, of such genes, or sets of genes. Also disclosed are methods for determining functionally related genes, or gene sets, as well as methods for treating cancer based on targeting expression products of such genes, or gene sets, and determining genes involved in the cancerous process.
PCT/US2001/010838 2000-06-05 2001-05-30 Cancer gene determination and therapeutic screening using signature gene sets WO2001094629A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP01938990A EP1358349A2 (en) 2000-06-05 2001-05-30 Cancer gene determination and therapeutic screening using signature gene sets
AU2001264559A AU2001264559A1 (en) 2000-06-05 2001-05-30 Cancer gene determination and therapeutic screening using signature gene sets
CA002411601A CA2411601A1 (en) 2000-06-05 2001-05-30 Cancer gene determination and therapeutic screening using signature gene sets
JP2002502169A JP2004509612A (en) 2000-06-05 2001-05-30 Oncogene determination and therapeutic screening using characteristic genes
US10/843,641 US20050064454A1 (en) 2000-06-05 2004-05-11 Cancer gene determination and therapeutic screening using signature gene sets

Applications Claiming Priority (84)

Application Number Priority Date Filing Date Title
US20947300P 2000-06-05 2000-06-05
US20953100P 2000-06-05 2000-06-05
US60/209,473 2000-06-05
US60/209,531 2000-06-05
US23361700P 2000-09-18 2000-09-18
US23313300P 2000-09-18 2000-09-18
US60/233,133 2000-09-18
US60/233,617 2000-09-18
US23405200P 2000-09-20 2000-09-20
US23403400P 2000-09-20 2000-09-20
US23400900P 2000-09-20 2000-09-20
US60/234,052 2000-09-20
US60/234,034 2000-09-20
US60/234,009 2000-09-20
US23456700P 2000-09-22 2000-09-22
US23450900P 2000-09-22 2000-09-22
US60/234,509 2000-09-22
US60/234,567 2000-09-22
US23513400P 2000-09-25 2000-09-25
US23508200P 2000-09-25 2000-09-25
US23492300P 2000-09-25 2000-09-25
US23528000P 2000-09-25 2000-09-25
US23492400P 2000-09-25 2000-09-25
US23507700P 2000-09-25 2000-09-25
US60/235,280 2000-09-25
US60/235,082 2000-09-25
US60/235,134 2000-09-25
US60/234,923 2000-09-25
US60/235,077 2000-09-25
US60/234,924 2000-09-25
US23563800P 2000-09-26 2000-09-26
US23563700P 2000-09-26 2000-09-26
US60/235,638 2000-09-26
US60/235,637 2000-09-26
US23572000P 2000-09-27 2000-09-27
US23571100P 2000-09-27 2000-09-27
US23584000P 2000-09-27 2000-09-27
US23586300P 2000-09-27 2000-09-27
US60/235,720 2000-09-27
US60/235,840 2000-09-27
US60/235,711 2000-09-27
US60/235,863 2000-09-27
US23603300P 2000-09-28 2000-09-28
US23603200P 2000-09-28 2000-09-28
US23602800P 2000-09-28 2000-09-28
US23603400P 2000-09-28 2000-09-28
US23610900P 2000-09-28 2000-09-28
US23611100P 2000-09-28 2000-09-28
US60/236,033 2000-09-28
US60/236,111 2000-09-28
US60/236,034 2000-09-28
US60/236,032 2000-09-28
US60/236,028 2000-09-28
US60/236,109 2000-09-28
US23689100P 2000-09-29 2000-09-29
US23684200P 2000-09-29 2000-09-29
US60/236,891 2000-09-29
US60/236,842 2000-09-29
US23731600P 2000-10-02 2000-10-02
US23727800P 2000-10-02 2000-10-02
US23729400P 2000-10-02 2000-10-02
US23717200P 2000-10-02 2000-10-02
US23717300P 2000-10-02 2000-10-02
US23729500P 2000-10-02 2000-10-02
US60/237,295 2000-10-02
US60/237,316 2000-10-02
US60/237,294 2000-10-02
US60/237,172 2000-10-02
US60/237,173 2000-10-02
US60/237,278 2000-10-02
US23760600P 2000-10-03 2000-10-03
US23760400P 2000-10-03 2000-10-03
US23759800P 2000-10-03 2000-10-03
US23760800P 2000-10-03 2000-10-03
US23742500P 2000-10-03 2000-10-03
US60/237,598 2000-10-03
US60/237,606 2000-10-03
US60/237,608 2000-10-03
US60/237,425 2000-10-03
US60/237,604 2000-10-03
US24508400P 2000-11-01 2000-11-01
US24486700P 2000-11-01 2000-11-01
US60/244,867 2000-11-01
US60/245,084 2000-11-01

Publications (3)

Publication Number Publication Date
WO2001094629A2 WO2001094629A2 (en) 2001-12-13
WO2001094629A8 WO2001094629A8 (en) 2002-05-16
WO2001094629A3 true WO2001094629A3 (en) 2003-09-04

Family

ID=27586968

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/010838 WO2001094629A2 (en) 2000-06-05 2001-05-30 Cancer gene determination and therapeutic screening using signature gene sets

Country Status (5)

Country Link
EP (1) EP1358349A2 (en)
JP (1) JP2004509612A (en)
AU (1) AU2001264559A1 (en)
CA (1) CA2411601A1 (en)
WO (1) WO2001094629A2 (en)

Families Citing this family (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777537B1 (en) 1996-02-22 2004-08-17 Forsyth Dental Infirmary For Children Osteoclast proton pump subunit
US20040219569A1 (en) 1999-07-06 2004-11-04 Fruma Yehiely Gene identification method
US20030236209A1 (en) * 1998-03-18 2003-12-25 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7258860B2 (en) 1998-03-18 2007-08-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7579160B2 (en) 1998-03-18 2009-08-25 Corixa Corporation Methods for the detection of cervical cancer
US20020147143A1 (en) * 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
ATE437947T1 (en) 1998-06-01 2009-08-15 Agensys Inc SERPENT TRANS MEMBRANE ANTIGENS EXPRESSED IN HUMAN CANCER AND THEIR USES
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
EP1637541B1 (en) * 1999-09-01 2010-03-03 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6893818B1 (en) 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
US7534417B2 (en) 2000-02-24 2009-05-19 Agensys, Inc. 103P2D6: tissue specific protein highly expressed in various cancers
US6953658B2 (en) 2000-03-09 2005-10-11 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating gastrointestinal cancer
CA2429196A1 (en) 2000-03-24 2001-10-04 Duke University Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto
US7235649B2 (en) 2000-03-24 2007-06-26 Duke University Isolated GRP94 ligand binding domain polypeptide and nucleic acid encoding same, and screening methods employing same
AU2001251034A1 (en) * 2000-03-31 2001-10-15 Gene Logic, Inc Gene expression profiles in esophageal tissue
IL151987A0 (en) * 2000-03-31 2003-04-10 Aventis Pharma Inc Nuclear factor kb inducing factor
GB0018307D0 (en) 2000-07-26 2000-09-13 Aventis Pharm Prod Inc Polypeptides
EP1666492A1 (en) * 2000-06-02 2006-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6524819B1 (en) * 2000-07-11 2003-02-25 Incyte Genomics, Inc. Down syndrome critical region 1-like proteins
US7291719B2 (en) 2000-07-25 2007-11-06 Genentech, Inc. PRO4332 antibodies
EP1666490A3 (en) * 2000-07-25 2006-11-02 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2001283062A1 (en) 2000-08-02 2002-02-13 The Johns Hopkins University Endothelial cell expression patterns
CA2417676A1 (en) * 2000-08-03 2002-02-14 Incyte Genomics, Inc. Sequences for integrin alpha-8
GB0020953D0 (en) * 2000-08-24 2000-10-11 Smithkline Beecham Biolog Vaccine
WO2002044357A2 (en) * 2000-11-30 2002-06-06 Millennium Pharmaceuticals, Inc. Methods of using 18903 to treat pain and pain-related disorders
MXPA03005004A (en) * 2000-12-08 2004-09-10 Protein Design Labs Inc Methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators.
US20020137184A1 (en) * 2000-12-20 2002-09-26 Pe Corporation (Ny) Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and use thereof
US7820447B2 (en) 2000-12-22 2010-10-26 Sagres Discovery Inc. Compositions and methods for cancer
US7700274B2 (en) 2000-12-22 2010-04-20 Sagres Discovery, Inc. Compositions and methods in cancer associated with altered expression of KCNJ9
US7892730B2 (en) 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
US20030194702A1 (en) * 2000-12-22 2003-10-16 Engelhard Eric K. Novel compositions and methods for cancer
US7645441B2 (en) 2000-12-22 2010-01-12 Sagres Discovery Inc. Compositions and methods in cancer associated with altered expression of PRLR
WO2002062958A2 (en) * 2001-02-08 2002-08-15 Tularik Inc. Prc17: an amplified cancer gene
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
US8647826B2 (en) 2001-03-14 2014-02-11 Agensys, Inc. Nucleic acid and corresponding protein entitled 125P5C8 useful in treatment and detection of cancer
EP1383543A4 (en) * 2001-03-23 2006-06-21 Agy Therapeutics Inc Use of biomolecular targets in the treatment and visualization of brain tumors
WO2002083921A2 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
US20050059001A1 (en) * 2001-05-31 2005-03-17 Akira Nakagawara Nucleic acids isolated in neuroblastoma
JP2004528046A (en) * 2001-06-05 2004-09-16 エクセリクシス・インコーポレイテッド DGKs as Modifiers of the p53 Pathway and Methods of Use
US20050272120A1 (en) 2001-06-20 2005-12-08 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
DK2000545T3 (en) 2001-06-20 2011-11-28 Genentech Inc Compositions and methods for diagnosis and treatment of lung tumor
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
JP2005505271A (en) 2001-09-06 2005-02-24 アジェンシス， インコーポレイテッド Nucleic acids and corresponding proteins given the name STEAP-1 useful in the treatment and detection of cancer
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US7157240B2 (en) 2001-09-18 2007-01-02 Bayer Healthcare Ag MID 4460, a human tyrosine phosphatase family member and uses therefor
WO2003035857A1 (en) * 2001-10-22 2003-05-01 Bayer Healthcare Ag Regulation of human nad-dependent alpha-glycerol-3-phosphate dehydrogenase
US7504222B2 (en) 2001-10-31 2009-03-17 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
JP4446036B2 (en) * 2001-11-27 2010-04-07 ウーセーベー ファルマ ソシエテ アノニム Pharmaceutical composition for the treatment of epithelial induced cancer
AU2003210554A1 (en) * 2002-01-18 2003-09-02 Millennium Pharmaceuticals, Inc. Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 or 6351 mo
CA2473990A1 (en) * 2002-02-01 2003-08-07 Beth Israel Deaconess Medical Center, Inc. Modulation of type ii.beta. phosphoinositide phosphate kinase
AU2003213743A1 (en) * 2002-03-06 2003-09-22 Avalon Pharmaceuticals Cancer-linked gene as target for chemotherapy
US20030215852A1 (en) * 2002-04-01 2003-11-20 Wyeth Novel pancortin-Pablo protein interactions and methods of use thereof
EP1361433A3 (en) * 2002-04-09 2005-02-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Method for estimating therapeutic efficacy of tumor necrosis factor (TNF)
CA2413475C (en) 2002-04-25 2010-07-27 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Zap-70 expression as a marker for chronic lymphocytic leukemia/small lymphocytic lymphoma (cll/sll)
US8076080B2 (en) 2002-05-21 2011-12-13 Sysmex Corporation Nucleic acid amplification primers for detecting cytokeratins and examination method with the use of the primers
EP1365244A1 (en) * 2002-05-23 2003-11-26 Bayer Ag Diagnostics and therapeutics for diseases associated with arginine vasopressin receptor 2 (AVPR2)
EP1365247A1 (en) * 2002-05-23 2003-11-26 Bayer Ag Diagnostics and therapeutics for diseases associated with arginine vasopressin receptor 3 (AVPR3)
EP2269628A3 (en) 2002-05-29 2011-04-20 DeveloGen Aktiengesellschaft Pancreas-specific proteins
AU2003245441A1 (en) * 2002-06-12 2003-12-31 Avalon Pharmaceuticals, Inc. Cancer-linked gene as target for chemotherapy
WO2003105783A2 (en) * 2002-06-12 2003-12-24 Avalon Pharmaceuticals, Inc. Cancer-linked gene as target for chemotherapy
AU2003246592A1 (en) * 2002-06-26 2004-01-19 Europroteome Ag Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases
GB0216727D0 (en) 2002-07-17 2002-08-28 Univ Cambridge Tech Genes
WO2004016784A1 (en) * 2002-08-06 2004-02-26 Genox Research, Inc. Protease inhibitor
AU2003243151A1 (en) 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
AU2002951346A0 (en) * 2002-09-05 2002-09-26 Garvan Institute Of Medical Research Diagnosis of ovarian cancer
AU2003264535A1 (en) 2002-09-27 2004-04-19 Noriyuki Sato Tumor antigen protein and utilization thereof
TW200413725A (en) * 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
DE60325628D1 (en) * 2002-09-30 2009-02-12 Oncotherapy Science Inc GENES AND POLYPEPTIDES IN CONNECTION WITH HUMAN PANCREATIC CARCINOMAS
EP1551443A2 (en) * 2002-10-14 2005-07-13 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Proteins involved in the regulation of energy homeostasis
AU2003279312A1 (en) * 2002-10-24 2004-05-13 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases
US7189524B1 (en) 2002-11-25 2007-03-13 Amgen, Inc. Receptor ligands and methods of modulating receptors
AU2003292737A1 (en) * 2002-12-24 2004-07-22 Takeda Pharmaceutical Company Limited Preventives/remedies for cancer
US7425624B1 (en) 2003-01-21 2008-09-16 Mayo Foundation For Medical Education And Research Sulfotransferase 1A3 sequence variants
WO2004066941A2 (en) * 2003-01-24 2004-08-12 Bayer Pharmaceuticals Corporation Expression profiles for colon cancer and methods of use
WO2004070062A2 (en) * 2003-02-04 2004-08-19 Wyeth Compositions and methods for diagnosing and treating cancers
AU2003900747A0 (en) * 2003-02-18 2003-03-06 Garvan Institute Of Medical Research Diagnosis and treatment of pancreatic cancer
US20080025989A1 (en) 2003-02-20 2008-01-31 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
WO2004073656A2 (en) 2003-02-20 2004-09-02 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
DE10309729A1 (en) * 2003-02-26 2004-09-16 Hinzmann, Bernd, Dr. Human nucleic acid sequences from bladder cancer
WO2004079013A1 (en) * 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
WO2004081174A2 (en) * 2003-03-10 2004-09-23 Japan Science And Technology Agency Marker for detecting mesenchymal stem cell and method of distinguishing mesenchymal stem cell using the marker
US20040191782A1 (en) * 2003-03-31 2004-09-30 Yixin Wang Colorectal cancer prognostics
ITRM20030149A1 (en) 2003-04-02 2004-10-03 Giuliani Spa ANTISENSE OLIGONUCLEOTIDES (ODN) FOR SMAD7 AND THEIR USE IN THE MEDICAL FIELD
FR2853909A1 (en) * 2003-04-16 2004-10-22 Galderma Res & Dev Using polynucleotide probes based on the DPYSL3 gene (Dihydropyrimidinase-like 3), for diagnosis of psoriasis, or predisposition, and in screening for antipsoriatic agents
US20060281088A1 (en) * 2003-05-21 2006-12-14 Wright Matthew B Markers for lxr activation
AU2004248140A1 (en) * 2003-05-30 2004-12-23 Cedars-Sinai Medical Center Gene expression markers for response to EGFR inhibitor drugs
KR20060034231A (en) 2003-06-06 2006-04-21 메디뮨 인코포레이티드 Use of epha4 and modulator of epha4 for diagnosis, treatment and prevention of cancer
EP1649064B1 (en) * 2003-07-17 2011-06-01 Pacific Edge Biotechnology Limited Markers for detection of gastric cancer
WO2005013893A2 (en) * 2003-07-24 2005-02-17 Avalon Pharmaceuticals, Inc. Cancer related genes
JP4643450B2 (en) 2003-08-08 2011-03-02 株式会社ペルセウスプロテオミクス Cancer high expression gene
JP2007502119A (en) * 2003-08-14 2007-02-08 エクセリクシス， インク． UPs as β-catenin pathway modifiers and methods of use
CA2475769C (en) * 2003-08-28 2018-12-11 Veridex, Llc Colorectal cancer prognostics
US20070178458A1 (en) * 2003-09-05 2007-08-02 O'brien Philippa Methods of diagnosis and prognosis of ovarian cancer II
US20050287544A1 (en) * 2003-12-01 2005-12-29 Francois Bertucci Gene expression profiling of colon cancer with DNA arrays
CA2549324A1 (en) * 2003-12-12 2005-06-30 Bayer Pharmaceuticals Corporation Gene expression profiles and methods of use
EP1709152A4 (en) * 2003-12-15 2007-11-07 Univ California Molecular signature of the pten tumor suppressor
GB0329997D0 (en) * 2003-12-24 2004-01-28 Cancer Rec Tech Ltd Methods for detecting neoplasia and markers thereof
US7264841B2 (en) 2004-01-21 2007-09-04 Linda Kalustian Lester Savory gluten-free foods
WO2005076005A2 (en) * 2004-01-30 2005-08-18 Medizinische Universität Wien A method for classifying a tumor cell sample based upon differential expression of at least two genes
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
TW200600785A (en) 2004-03-23 2006-01-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancer
EP1730533A1 (en) * 2004-03-24 2006-12-13 Oncotherapy Science, Inc. Adam8 as tumor marker and therapeutic target for non-small cell lung cancer
EP1735461A4 (en) * 2004-04-06 2008-10-29 Univ California Orphan receptor tyrosine kinase as a target in breast cancer
JPWO2005097204A1 (en) 2004-04-09 2008-02-28 武田薬品工業株式会社 Cancer preventive / therapeutic agent
WO2005113601A2 (en) 2004-04-22 2005-12-01 Agensys, Inc. Antibodies and molecules derived therefrom that bind to steap-1 proteins
US7482129B2 (en) * 2004-05-04 2009-01-27 Institute Of Virology, Slovak Academy Of Sciences MN/CA IX/CA9 and Renal Cancer Prognosis
DE102004023187A1 (en) * 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumor diagnosis and therapy
AU2013206612B2 (en) * 2004-05-11 2016-04-28 Biontech Ag Identification of surface-associated antigens for tumor diagnosis and therapy
AU2012200098B2 (en) * 2004-05-11 2014-05-08 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumour diagnosis and therapy
WO2005118869A2 (en) * 2004-05-28 2005-12-15 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US20120258442A1 (en) 2011-04-09 2012-10-11 bio Theranostics, Inc. Determining tumor origin
CN101035909A (en) 2004-06-04 2007-09-12 阿威亚拉德克斯股份有限公司 Identification of tumors
AU2005258331B2 (en) * 2004-06-24 2009-12-10 Veridex, Llc Methods and reagents for the detection of melanoma
WO2006027693A2 (en) * 2004-09-09 2006-03-16 Exonhit Therapeutics Sa Tumor specific genes and variant rnas and uses thereof as targets for cancer therapy and diagnosis
CA2584862A1 (en) * 2004-10-13 2006-04-27 A&G Pharmaceutical, Inc. Autocrine growth factor receptors and methods
US8337838B2 (en) 2004-10-15 2012-12-25 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
CA2583208C (en) 2004-10-15 2015-08-25 Seattle Genetics, Inc. Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders
US7641903B2 (en) 2004-10-15 2010-01-05 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
WO2006053442A1 (en) * 2004-11-22 2006-05-26 Diagnocure Inc. Calml3 a specific and sensitive target for lung cancer diagnosis, prognosis and/or theranosis
WO2006056080A1 (en) * 2004-11-29 2006-06-01 Diagnocure Inc. Gpx2 a specific and sensitive target for lung cancer diagnosis, prognosis and/or theranosis
JP2006174731A (en) * 2004-12-21 2006-07-06 Seikagaku Kogyo Co Ltd Translocation agent and method for detecting canceration of tissue
KR100664587B1 (en) * 2004-12-22 2007-01-04 김현기 Human cancer suppressor gene protein encoded therein expression vector containing same and cell transformed by said vector
US8535914B2 (en) * 2005-01-21 2013-09-17 Canon Kabushiki Kaisha Probe, probe set and information acquisition method using the same
KR100689274B1 (en) * 2005-03-30 2007-03-08 김현기 Human protooncogene and protein encoded by same
DK1871418T3 (en) 2005-04-19 2014-06-10 Seattle Genetics Inc Humanized anti-CD70 binding agents and uses thereof
EP1897940A4 (en) 2005-05-02 2009-04-15 Toray Industries Composition and method for diagnosing esophageal cancer and metastasis of esophageal cancer
US20070037186A1 (en) * 2005-05-20 2007-02-15 Yuqiu Jiang Thyroid fine needle aspiration molecular assay
KR20080104113A (en) 2005-06-03 2008-12-01 아비아라디엑스, 인코포레이티드 Identification of tumors and tissues
US8716021B2 (en) 2005-09-07 2014-05-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of replicators to prevent gene silencing
EP1957672A2 (en) * 2005-10-28 2008-08-20 Biomerieux Sa Method for detecting cancer
GB0526498D0 (en) * 2005-12-28 2006-02-08 Randox Lab Ltd Method
US20080058432A1 (en) * 2006-03-03 2008-03-06 Yixin Wang Molecular assay to predict recurrence of Duke's B colon cancer
GB0606954D0 (en) * 2006-04-06 2006-05-17 Randox Lab Ltd Method
AR053600A1 (en) * 2006-04-28 2007-05-09 Fundacion Inst Leloir AN ISOLATED DNA FRAGMENT FROM THE A33 HUMAN PROMOTER AND ITS USE TO DIRECT THE EXPRESSION OF A HETEROLOGICAL GENE IN TUMOR CELLS
WO2008024009A1 (en) * 2006-08-15 2008-02-28 Institut Molekulyarnoi Genetiki Rossiiskoi Akademii Nauk (Img Ran) Transcriptional level of a timp3 gene in the form of a diagnosis marker of a non-small cell carcinoma of lung
EP2052739A4 (en) * 2006-08-16 2010-01-06 Forerunner Pharma Res Co Ltd Cancer therapeutic agent comprising ligand for neuromedin u receptor 2 (fm4) molecule as active ingredient
CA2667019C (en) 2006-10-27 2016-03-29 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
US7812002B2 (en) 2007-03-21 2010-10-12 Quark Pharmaceuticals, Inc. Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer
US8822153B2 (en) 2007-06-01 2014-09-02 The University Of North Carolina At Chapel Hill Molecular diagnosis and typing of lung cancer variants
EP2592156B1 (en) * 2007-06-08 2016-04-20 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
ES2437122T3 (en) * 2007-08-14 2014-01-09 F. Hoffmann-La Roche Ag Predictive marker in EGFR inhibitor treatment
DK2644712T3 (en) * 2007-10-23 2018-08-20 Clinical Genomics Pty Ltd A method for diagnosing neoplasms
JP2011511635A (en) * 2008-02-11 2011-04-14 ハダシット メディカル リサーチ サービシーズ アンド ディベロップメント リミテッド Colon cancer associated transcription factor 1 (CCAT-1) as a cancer marker
MY159553A (en) 2008-04-11 2017-01-13 Seattle Genetics Inc Detection and treatment of pancreatic, ovarian and other cancers
PL2282773T3 (en) 2008-05-02 2014-08-29 Seattle Genetics Inc Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
EP2363468B1 (en) 2008-10-20 2014-12-31 Sapporo Medical University Tumor antigen peptide and use thereof
US8211434B2 (en) 2008-11-26 2012-07-03 Allergan, Inc. KLK-13 antibody inhibitor for treating dry eye
WO2011009036A1 (en) * 2009-07-16 2011-01-20 Soymeds, Inc. Soybean derived human thyroglobulin, methods of producing and applications thereof
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
ES2874306T3 (en) 2010-09-29 2021-11-04 Agensys Inc Conjugates of antibodies and drugs (CAF) that bind to 191P4D12 proteins
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
EP3224377B1 (en) * 2014-11-25 2020-01-01 AIT Austrian Institute of Technology GmbH Diagnosis of lung cancer
JP2016214239A (en) * 2015-05-15 2016-12-22 国立大学法人高知大学 Pancreatic cancer marker
BR112019018767A2 (en) 2017-04-03 2020-05-05 Hoffmann La Roche antibodies, bispecific antigen binding molecule, one or more isolated polynucleotides, one or more vectors, host cell, method for producing an antibody, pharmaceutical composition, uses, method for treating a disease in an individual and invention
TW202138388A (en) 2019-12-30 2021-10-16 美商西根公司 Methods of treating cancer with nonfucosylated anti-cd70 antibodies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019369A1 (en) * 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer
US5882874A (en) * 1998-02-27 1999-03-16 The Trustees Of Columbia University In The City Of New York Reciprocal subtraction differential display
WO1999050278A1 (en) * 1998-03-31 1999-10-07 Genzyme Corporation Compositions and methods for the identification of lung tumor cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019369A1 (en) * 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer
US5882874A (en) * 1998-02-27 1999-03-16 The Trustees Of Columbia University In The City Of New York Reciprocal subtraction differential display
WO1999050278A1 (en) * 1998-03-31 1999-10-07 Genzyme Corporation Compositions and methods for the identification of lung tumor cells

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHENG L ET AL: "Characterisations of taxol-induced apoptosis and altered gene expression in human breast cancer cells.", CELLULAR PHARMACOLOGY, vol. 2, no. 6, 1995, pages 249 - 257, XP008013734, ISSN: 1351-3214 *
DATABASE EBI [online] 3 August 1996 (1996-08-03), HILLIER, L. ET AL.: "ze23c03.s1 Soares fetal heart, H. sapiens cDNA clone, mRNA sequence;", XP002230815, retrieved from EMBL Database accession no. AA011199 *
HESS J ET AL: "Application of differential cDNA screening techniques to the identification of unique gene expression in tumours and lymphocytes", CURRENT OPINION IN IMMUNOLOGY, CURRENT BIOLOGY LTD, XX, vol. 10, no. 2, April 1998 (1998-04-01), pages 125 - 130, XP004327175, ISSN: 0952-7915 *
KURDISTANI SIAVASH K ET AL: "Inhibition of tumor cell growth by RTP/rit42 and its responsiveness to p53 and DNA damage.", CANCER RESEARCH, vol. 58, no. 19, 1 October 1998 (1998-10-01), pages 4439 - 4444, XP001109678, ISSN: 0008-5472 *
SIAVOSHIAN S ET AL: "Subtractive hybridization and differential screening identified two genes differentially expressed after induction of in vitro (atypical) terminal differentiation in the NSCLC-N6 cell line by a marine substance (bistramide K).", ANTICANCER RESEARCH., vol. 19, no. 6b, November 1999 (1999-11-01), pages 5361 - 5366, XP008013799, ISSN: 0250-7005 *
VIETOR I ET AL: "In search of differentially expressed genes and proteins", BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR CELL RESEARCH, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 1359, no. 3, 12 December 1997 (1997-12-12), pages 187 - 199, XP004277797, ISSN: 0167-4889 *

Also Published As

Publication number Publication date
CA2411601A1 (en) 2001-12-13
WO2001094629A2 (en) 2001-12-13
AU2001264559A1 (en) 2001-12-17
AU2001264559A8 (en) 2001-12-17
WO2001094629A8 (en) 2002-05-16
EP1358349A2 (en) 2003-11-05
JP2004509612A (en) 2004-04-02

Similar Documents

Publication Publication Date Title
WO2001094629A3 (en) Cancer gene determination and therapeutic screening using signature gene sets
WO2003021227A3 (en) Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors
MXPA03002862A (en) Cancer diagnostic panel.
WO2003009814A3 (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
WO2001070979A3 (en) Genes, compositions, kits, and method for identification, assessment, prevention and therapy of ovarian cancer
WO2000028090A3 (en) Diagnostic assay for cancer
WO1998053319A3 (en) Gene expression profiles in normal and cancer cells
WO2002092854A3 (en) Genes expressed in breast cancer as prognostic and therapeutic targets
WO2003072125A8 (en) Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides
WO2004070062A3 (en) Compositions and methods for diagnosing and treating cancers
WO2004031413A3 (en) Method for diagnosing non-small cell lung cancers
WO2002071928A3 (en) Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
WO2003004989A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2002059373A3 (en) Genes overexpressed in prostate disorders as diagnostic and therapeutic targets
WO2006028655A3 (en) Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
AU2003260966A1 (en) Genes and polypeptides relating to human pancreatic cancers
TW200600785A (en) Method for diagnosing non-small cell lung cancer
MXPA03003281A (en) Non-invasive enzyme screen for tissue remodelling-associated conditions.
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2006034456A3 (en) Compositions and methods for detecting and treating tumors
WO2004047767A3 (en) Methods for identifying risk of breast cancer and treatments thereof
WO2001036685A3 (en) Differential gene expression in cancer
WO2002010436A3 (en) Prognostic classification of breast cancer
WO2002031209A3 (en) Genes related to development of refractory prostate cancer
WO2005014846A3 (en) Methods for identifying risk of breast cancer and treatments thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 50/2001 UNDER "PUBLISHED", DELETE "SEQUENCE LISTING PART OF DESCRIPTION PUBLISHED SEPARATELY IN ELECTRONIC FORM AND AVAILABLE UPON REQUEST FROM THE INTERNATIONAL BUREAU."

CFP Corrected version of a pamphlet front page
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2001938990

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2411601

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2002 502169

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2001938990

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001938990

Country of ref document: EP